Antibody Discovery Platform for Target Identification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The identification of cancer-specific targets for therapeutic antibodies remains a bottleneck in the development of new cancer treatments, despite the success of molecularly targeted antibody therapies.
Innovation Solution
A high-throughput platform for the simultaneous discovery of therapeutic antibodies and their associated targets based on phenotypic binding profiles, involving affinity selection and analysis of input and output libraries to identify antibodies and their targets.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional target identification methods are used, then antibody development can proceed, but the identification process remains a bottleneck and is time-consuming
Solution Approach 1:
The patent combines antibody discovery and target identification into a single integrated platform. The system simultaneously identifies both therapeutic antibodies and their targets through phenotypic binding profile analysis, eliminating the sequential process where target identification was a separate bottleneck step.
Solution Approach 2:
The patent replaces traditional mechanical/target-focused identification methods with a phenotypic binding profile-based approach. By using high-throughput screening and computational analysis of binding profiles, the system accelerates target identification without requiring traditional step-by-step mechanical screening processes.
2Productivity
If high-throughput screening is implemented, then antibody discovery efficiency increases, but the complexity of the platform increases
Solution Approach 1:
The patent creates a universal platform that performs multiple functions: it screens for antibodies, identifies their binding profiles, determines target antigens, and characterizes phenotypic properties all within a single integrated system. This multi-functionality increases productivity while managing complexity through consolidation rather than multiplication of separate systems.
Data Source
AI summary
The invention is directed to a high throughput platform for the simultaneous discovery of therapeutic antibodies and associated targets based on their phenotypic binding profiles, and monoclonal antibodies discovered therewith.